NRX Pharmaceuticals, Inc. financial data

Symbol
NRXP, NRXPW on Nasdaq
Industry
Pharmaceutical Preparations
Location
1201 Orange Street, Suite 600, Wilmington, DE
State of incorporation
DE
Fiscal year end
December 31
Former names
Big Rock Partners Acquisition Corp. (to 5/24/2021)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 74.1 %
Debt-to-equity -133 % +96.9%
Return On Equity 127 % -98.3%
Return On Assets -391 % -118%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.1M shares -85.6%
Common Stock, Shares, Outstanding 11.4M shares -86.4%
Entity Public Float 29.7M USD
Common Stock, Value, Issued 11K USD -86.9%
Weighted Average Number of Shares Outstanding, Basic 11M shares +33.9%
Weighted Average Number of Shares Outstanding, Diluted 8.85M shares +33.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.7M USD -49.7%
General and Administrative Expense 12.8M USD -28.1%
Operating Income (Loss) -20.5M USD +38.5%
Nonoperating Income (Expense) 96K USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -20.4M USD +43.5%
Earnings Per Share, Basic 1.57 USD/shares +79.7%
Earnings Per Share, Diluted -0.74 USD/shares +55.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.65M USD -81.5%
Other Assets, Current 128K USD
Assets, Current 4.11M USD -68.6%
Other Assets, Noncurrent 356K USD +1595%
Assets 4.46M USD -66%
Accounts Payable, Current 4.87M USD +34%
Employee-related Liabilities, Current 324K USD
Accrued Liabilities, Current 5.3M USD +4.79%
Contract with Customer, Liability, Current 56K USD -95.6%
Liabilities, Current 20.3M USD +5.03%
Liabilities 23.3M USD +20.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -269M USD -8.19%
Stockholders' Equity Attributable to Parent -18.8M USD -203%
Liabilities and Equity 4.46M USD -66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.67M USD +39.7%
Net Cash Provided by (Used in) Financing Activities 395K USD -84.5%
Net Cash Provided by (Used in) Investing Activities -4K USD -33.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 11.4M shares -86.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.32M USD -92%
Interest Paid, Excluding Capitalized Interest, Operating Activities 374K USD
Deferred Tax Assets, Valuation Allowance 44.9M USD +6.78%
Deferred Tax Assets, Gross 44.9M USD +6.78%
Depreciation 1K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.63M USD +73.2%
Deferred Tax Assets, Operating Loss Carryforwards 35.9M USD +6.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Additional Paid in Capital 250M USD +3.23%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 104K USD -70.4%
Interest Expense 230K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%